Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women in the United States. It provides OVA1, Overa, and Ova1PLUS to detect the risk of ovarian malignancy. The company also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, it owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, the company is developing diagnostic algorithms; and a high-risk screening algorithm for patients who are genetically predisposed to ovarian cancer. It has entered into a collaborative research agreement with Baylor Genetics to co-develop a novel ovarian cancer early-detection test; and an agreement with Dana Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer. The company has a strategic alliance with Quest Diagnostics, Incorporated. It serves physician office and hospital laboratories, as well as physicians. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas.
IPO Year:
Exchange: NASDAQ
Website: aspirawh.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/12/2022 | $4.00 | Overweight | Cantor Fitzgerald |
Interim CFO John Kallassy to Depart January 10 AUSTIN, TX / ACCESSWIRE / January 10, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of Mike Buhle as SVP of Commercial Operations.Mr. Buhle has over 25 years of experience driving commercial growth and new product launches in the diagnostics and life science tools domains, working for start-up, scale-up, and established businesses. He brings hands-on leadership experience in clinical diagnostics specializing in precision medicine and patient outcomes in oncology, rare dise
AUSTIN, Texas, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that Nicole Sandford, Chief Executive Officer (CEO) and Board member, will be departing the Company to focus on a family health matter. Aspira's President Dr. Sandra Milligan will step into the role of interim CEO while a nationwide search of internal and external candidates is conducted. Ms. Sandford's departure will be effective immediately. She will remain as a consultant to ensure a seamless transition. "The Board thanks Nicole for the outst
AUSTIN, Texas, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the successful completion of the first development milestone of its Advanced Research Projects Agency for Health (ARPA-H) award. As a result, Aspira has received a $2 million cash payment under the terms of the related agreement. ARPA-H's Sprint for Women's Health was created to address critical unmet challenges in women's health, champion transformative innovations, and tackle health conditions that uniquely or disproportionately affect women. As previously a
Q3 2024 OvaSuiteSM revenue of $2.3 million and volume of 6,001 units Cash utilization for the third quarter was $2.9 million, a decrease of 12% compared to the second quarter of 2024 Full year 2024 cash guidance reconfirmed as $13.0-$14.5 million Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today reported selected financial results for the third quarter ended September 30, 2024. "OvaWatch® product volume, which we believe is the most import
AUSTIN, Texas, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the expansion of its co-marketing and distribution collaboration with BioReference Health, LLC ("BioReference"), a wholly-owned subsidiary of OPKO Health Inc. (NASDAQ:OPK), a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets. Under the terms of the expanded agreement, Aspira and BioReference will join forces to market Aspira's complete OvaSuite portfolio, including OvaWa
AUSTIN, Texas, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three and nine months ended September 30, 2024, on Thursday, November 14, 2024. Management will also host a conference call at 8:30 am ET to discuss financial results and provide a corporate update. Details of the call are as follows: Conference Call & Webcast Details:Date:Thursday, November 14, 2024Time:8:30 am ETToll Free:877-545-0320International:973-528-0002Access Code:436613Webcast:R
AUSTIN, Texas, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, has issued a letter to Company shareholders and announced it will host a virtual Research & Development Day on Tuesday, October 29, 2024, at 3:00 pm ET. The R&D Day will highlight the company's plans for its miRNA development pipeline, including the recently announced award from the Advanced Research Project Agency for Health (ARPA-H)'s Sprint for Women's Health initiative for ENDOinform™. Details for the event are as follows: Date:October 29, 2024Time:3:00 pm ETTo register:Cli
AUSTIN, Texas, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced it has been selected by the Advanced Research Projects Agency for Health (ARPA-H) as an awardee of the Sprint for Women's Health to address critical unmet challenges in women's health, champion transformative innovations, and tackle health conditions that uniquely or disproportionately affect women. Aspira will receive $10 million in funding over two years through the Sprint for Women's Health launchpad track for later-stage health solutions. Funding from the pr
AUSTIN, Texas, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that it has received approval from the New York State Department of Health's (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) for OvaWatch®, the Company's non-invasive blood test for the assessment of ovarian cancer risk for women with an adnexal mass determined by initial clinical assessment as indeterminate or benign, and thus surgery may be premature or unnecessary. NYSDOH/CLEP approval is required for all lab developed tests to ensure compliance wi
AUSTIN, Texas, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the publication of a paper in the journal Gynecologic Oncology highlighting data demonstrating that a multimodal assay combining miRNA with protein biomarkers, age, and menopausal status offered the most accurate classification of patients with an adnexal mass for the identification of early-stage ovarian cancer. The study, entitled: "Serum miRNA improves the accuracy of a multivariate index assay for triage of an adnexal mass," analyzed serum samples from
SC 13G - Aspira Women's Health Inc. (0000926617) (Subject)
SC 13D/A - Aspira Women's Health Inc. (0000926617) (Subject)
SC 13D/A - Aspira Women's Health Inc. (0000926617) (Subject)
SC 13G/A - Aspira Women's Health Inc. (0000926617) (Subject)
SC 13G - Aspira Women's Health Inc. (0000926617) (Subject)
SC 13D/A - Aspira Women's Health Inc. (0000926617) (Subject)
SC 13G/A - Aspira Women's Health Inc. (0000926617) (Subject)
SC 13D/A - Aspira Women's Health Inc. (0000926617) (Subject)
SC 13G/A - Aspira Women's Health Inc. (0000926617) (Subject)
SC 13G - Aspira Women's Health Inc. (0000926617) (Subject)
AUSTIN, Texas, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that Nicole Sandford, Chief Executive Officer (CEO) and Board member, will be departing the Company to focus on a family health matter. Aspira's President Dr. Sandra Milligan will step into the role of interim CEO while a nationwide search of internal and external candidates is conducted. Ms. Sandford's departure will be effective immediately. She will remain as a consultant to ensure a seamless transition. "The Board thanks Nicole for the outst
AUSTIN, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that it was selected as a spoke for the Investor Catalyst Hub, a regional hub of ARPANET-H, a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H). Based in the Greater Boston area and managed by VentureWell, the Investor Catalyst Hub seeks to accelerate the commercialization of groundbreaking and accessible biomedical solutions. It utilizes an innovative hub-and-spoke model designed to reach a wide range of
AUSTIN, Texas, July 29, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of Mr. John Ragard to its Board of Directors. Mr. Ragard is an accomplished executive with extensive experience successfully managing several billion-dollar portfolios over his career. "We are pleased to welcome John to our Board of Directors," said Ms. Jannie Herchuk, Chairwoman of the Board at Aspira Women's Health. "John brings a wealth of experience and a keen understanding of Wall Street, having been a successful money manager for the past
Dr. Milligan brings a wealth of experience across critical business functions and deep relationships with leaders throughout the healthcare and pharmaceutical sectors Aspira also announces Dr. Todd Pappas, Vice President of Research & Development, to lead the Company's product development team following the departure of Dr. Jody Berry AUSTIN, Texas, March 18, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that it has expanded its senior management team with the addition of Sandra Milligan, M.D., J.D. as President
WALTHAM, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, is pleased to announce changes to its Board of Directors reflecting a strategic move to further align with the company's growth plans. After nearly a decade of service, Gus Halas is retiring from his position as Chairperson of the Board. During his tenure, he played a pivotal role in shaping OptimizeRx's success, and we extend our deepest gratitude for his commitment and leadership. Effective immediately, Lynn O'Connor Vos will assume the role o
AUSTIN, Texas, June 05, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of Dr. Winfred Parnell as a new independent director on the Aspira Board of Directors, effective June 1, 2023. "We are thrilled to welcome Dr. Parnell to our Board of Directors. He is a respected leader with a unique combination of experiences. Not only has he spent more than four decades as an obstetrician and gynecologist, he has chaired the board of one of the largest public health systems in the country," said Dr. Veronica Jordan, Aspira's Ch
AUSTIN, Texas, May 09, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced it the appointment of three new independent directors: Stefanie Cavanaugh, Jannie Herchuck, and Lynn O'Connor Vos. "We are thrilled to welcome Stefanie, Jannie and Lynn to our Board of Directors," said Dr. Veronica Jordan, Chairwoman of the Aspira Board of Directors. "Aspira has been through tremendous change this past year, and attracting top talent is a testament to the strength of the technology, strategy and potential as a company. We look forward to their
AUSTIN, Texas, June 23, 2022 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira"), a bio-analytical based women's health company focused on gynecologic disease, today announced the appointments of two seasoned Board members: Dr. Robert Auerbach and Ms. Ruby Sharma. Dr. Auerbach retired President of CooperSurgical Inc., brings extensive experience in the medical industry, including experience as a director and as an executive officer. Ms. Sharma, Managing Partner at RNB Strategic Advisors, brings decades of senior leadership, accounting, and audit committee experience. "We warmly welcome both Bob and Ruby to our Board. Each brings different - but equally critical - skills and experti
AUSTIN, Texas, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (NASDAQ:AWH), a bioanalytical-based women's health company, today announced the appointment of Celeste Fralick, Ph.D., to its Board of Directors, effective February 23, 2022. Dr. Fralick is an accomplished executive with over four decades of data strategy experience. She brings to the Board a broad background in technology and specifically healthcare in several markets with both customer and industry-facing experience. She has expertise in statistics, cybersecurity, system engineering, disability analyses, risk management, operations, quality systems, global regulatory affairs, clinical management, biotechnology,
AUSTIN, Texas, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Aspira Women's Health, Inc. (NASDAQ:AWH), a bioanalytical-based women's health company, today announced the appointment of Mr. Michael Newton as Head of Sales and Marketing who brings to the company over twenty years of experience in the diagnostic healthcare area. In this role, Mr. Newton will be responsible for overseeing the Company's entire U.S. commercialization strategy, including current products, new products and future services. He will lead the national sales force, driving adoption of the OVA1Plus product and establishing it as the standard of care for early risk detection of ovarian cancer, helping to achieve the goal of establi
Cantor Fitzgerald resumed coverage of Aspira Women's Health with a rating of Overweight and set a new price target of $4.00
Truist Securities initiated coverage of Aspira Womens Health with a rating of Buy and set a new price target of $12.00
Cantor Fitzgerald initiated coverage of Aspira Womens Health with a rating of Overweight and set a new price target of $10.00
4 - Aspira Women's Health Inc. (0000926617) (Issuer)
4 - Aspira Women's Health Inc. (0000926617) (Issuer)
4 - Aspira Women's Health Inc. (0000926617) (Issuer)
4 - Aspira Women's Health Inc. (0000926617) (Issuer)
4 - Aspira Women's Health Inc. (0000926617) (Issuer)
4 - Aspira Women's Health Inc. (0000926617) (Issuer)
4 - Aspira Women's Health Inc. (0000926617) (Issuer)
4 - Aspira Women's Health Inc. (0000926617) (Issuer)
4 - Aspira Women's Health Inc. (0000926617) (Issuer)
4 - Aspira Women's Health Inc. (0000926617) (Issuer)
4 - Aspira Women's Health Inc. (0000926617) (Issuer)
4 - Aspira Women's Health Inc. (0000926617) (Issuer)
4/A - Aspira Women's Health Inc. (0000926617) (Issuer)
4 - Aspira Women's Health Inc. (0000926617) (Issuer)
4 - Aspira Women's Health Inc. (0000926617) (Issuer)
Q3 2024 OvaSuiteSM revenue of $2.3 million and volume of 6,001 units Cash utilization for the third quarter was $2.9 million, a decrease of 12% compared to the second quarter of 2024 Full year 2024 cash guidance reconfirmed as $13.0-$14.5 million Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today reported selected financial results for the third quarter ended September 30, 2024. "OvaWatch® product volume, which we believe is the most import
AUSTIN, Texas, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three and nine months ended September 30, 2024, on Thursday, November 14, 2024. Management will also host a conference call at 8:30 am ET to discuss financial results and provide a corporate update. Details of the call are as follows: Conference Call & Webcast Details:Date:Thursday, November 14, 2024Time:8:30 am ETToll Free:877-545-0320International:973-528-0002Access Code:436613Webcast:R
AUSTIN, Texas, July 31, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months ended June 30, 2024, on Monday, August 12, 2024. Management will also host a conference call at 4:30 p.m. Eastern Time to discuss financial results and provide a corporate update. Details for the call are as follows: Conference Call & Webcast Details:Date: Monday, August 12, 2024Time: 4:30 p.m. ETToll Free:877-407-4018Webcast:Click HERE A replay of the webcast will also be
AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months ended March 31, 2024, on Wednesday, May 15, 2024. Management will also host a conference call at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. Details for the call are as follows: Conference Call & Webcast Details:Date:Tuesday, May 14, 2024Time:8:30 a.m. Eastern TimeToll Free:877-407-4018Webcast:Click HERECall me™:Click HERE Participants
AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months and year ended December 31, 2023, on Thursday, March 28, 2024. Management will also host a conference call at an updated time of 8:30 am ET to discuss financial results and provide a corporate update. Details for the call are as follows: Conference Call & Webcast Details:Date: Thursday, March 28, 2024Time: 8:30 am ET (NEW TIME)Toll Free: 877-407-4018International: 201-689-
AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months and year ended December 31, 2023 on Thursday, March 28, 2024. Management will also host a conference call at 4:30 pm to discuss financial results and provide a corporate update. Details for the call are as follows: Conference Call & Webcast Details: Date:Thursday, March 28, 2024Time:4:30 pmToll Free:877-407-4018International:201-689-8471Webcast:Click HERECall MeTM:Click HER
AUSTIN, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira"), a bio-analytical company focused on the development and commercialization of women's health diagnostic tools for gynecologic diseases, today announced that the company will report its financial results for the three months ended September 30, 2023 on Monday, November 13, 2023. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30 p.m. Eastern Time. Details for the call are as follows: Conference call & Webcast Details:Date:Monday, November 13Time:4:30 p.m. Eastern TimeToll Free:1-877-407-4018International:1-201-689-8471Webcast:cl
AUSTIN, Texas, July 31, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira"), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the company will report its financial results for the three months ended June 30, 2023 on Monday, August 14, 2023. Management will host a conference call to discuss financial results and provide a corporate update at 4:30 pm Eastern Time. Details for the call are as follows: Conference call & Webcast Details:Date:Monday, August 14Time:4:30 pm Eastern TimeToll Free:1-877-407-4018International:1-201-689-8471Webcast:Click HERE A replay of the webcast will be available o
First Quarter total product revenue of $2.3 million, an increase of 26% year-over-year First Quarter OvaSuite volume of 6,259 units, an increase of 29% year-over-year First Quarter cash used in operations of $5.7 million, a decrease of 44% year-over-year Conference Call and Webcast scheduled for today 4:30 pm Eastern Time AUSTIN, Texas, May 11, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today reported its financial results for the first quarter ended March 31, 2023. "We saw record growth in both revenues and volume in the first quarter of
Preliminary first quarter 2023 volume was 6,259 tests, an increase of 29% compared to last year, the highest volume quarter in the company's history Management to host its first quarter earnings conference call on Thursday, May 11 at 4:30 pm AUSTIN, Texas, April 27, 2023 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira"), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced preliminary first quarter OvaSuite volume and earnings conference call details. Preliminary First Quarter Highlights Preliminary OvaSuite volume increased 29% to 6,259 tests performed during the quarter ended March 31, 2023,
8-K - Aspira Women's Health Inc. (0000926617) (Filer)
S-1 - Aspira Women's Health Inc. (0000926617) (Filer)
8-K - Aspira Women's Health Inc. (0000926617) (Filer)
8-K - Aspira Women's Health Inc. (0000926617) (Filer)
8-K - Aspira Women's Health Inc. (0000926617) (Filer)
10-Q - Aspira Women's Health Inc. (0000926617) (Filer)
NT 10-Q - Aspira Women's Health Inc. (0000926617) (Filer)
8-K - Aspira Women's Health Inc. (0000926617) (Filer)
8-K - Aspira Women's Health Inc. (0000926617) (Filer)
8-K - Aspira Women's Health Inc. (0000926617) (Filer)